A newly formed company called Murano Bidco, which is controlled by the Carlyle Group, has agreed to pay approximately £958 million to acquire inhalation CDMO Vectura, the companies have announced. According to the announcement, Bidco was formed specifically for the purpose of acquiring Vectura.
Vectura Chairman Bruno Angelici commented, “Vectura has made strong progress since embarking on its new strategy in 2019 to become a leading inhalation focused CDMO, whilst continuing to deliver strong financial and operational results in its royalties and product supply businesses. While the Vectura directors remain confident in the long term fundamentals of the Vectura Group, we believe that this is an attractive offer for Vectura shareholders, which secures the delivery of future value for Vectura shareholders in cash today. The offer reflects the quality, strength and long term performance of Vectura’s businesses and its future growth potential. We believe that our people, our clients and our businesses will continue to prosper under the stewardship of Carlyle.”
Carlyle Group Managing Director Simon Dingemans said, “We have followed the strategic changes underway at Vectura closely and fully support the focus on building a market leading inhalation specialist CDMO. We believe that under Carlyle’s ownership Vectura will be able to accelerate its transformation significantly with greater access to capital and the support of our long experience in the sector. We look forward to working with Will Downie and his team.”
Vectura recently announced a development deal with Inspira related to an inhaled COVID-19 therapy. Earlier this year, the company announced an expansion of its DPI manufacturing capacity.
Read the Vectura announcement.
